Abstract:Abstract As the energy factory for the cell, the mitochondrion, through its role of ATP production by oxidative phosphorylation, can be regarded as the guardian of well regulated cellular metabolism; the integrity of mitochondrial functions, however, is particularly vulnerable in cancer due to the lack of superstructures such as histone and lamina folds to protect the mitochondrial genome from unintended exposure, which consequently elevates risks of mutation. In cancer, mechanisms responsible for enforcing quality control surveillance for identifying and eliminating defective mitochondria are often poorly regulated, and certain uneliminated mitochondrial DNA (mtDNA) mutations and polymorphisms can be advantageous for the proliferation, progression, and metastasis of tumor cells and disseminated into microenvironment cells through extracellular vesicle and tunnel nano tube. Such pathogenic mtDNA aberrations are likely to increase and frequently be homoplasmic in metastatic cancer cells and, intriguingly, in normal cells in the tumor microenvironments as well. Distinct characteristics of these abnormalities in mtDNA may provide a new path for cancer therapy. We recently tested this hypothesis with a few PIP-TPP conjugates targeting mtDNA mutations to induce mutants reduction in heteoplasmic cells or apoptosis in homoplasmic or near homoplasmic cells in vivo model without major adverse effects. This finding reaffirms the feasibility of such a PIP-TPP-based mtDNA-targeting approach for anticancer therapy as well as perhaps cancer risk prevention. However, the absence of known mtDNA mutation hotspots limits the clinical application of somatic mutation-targeted PIP-TPPs. Thus, we designed CCCh-1005-TPP to selectively target a frequent ATP6 gene variant and often oncogenically homoplasmic in the associated with hypertrophic cardiomyopathy, colon, breast and ovarian cancer risk and found its anticancer effect in mouse xenograft models. Here we study preclinical trial of CCCh-1005-TPP, a promising novel anti-cancer agent for clearing abnormal mtDNA by reactivating mitochondrial quality control surveillance of mitophagy. Given those mechanistic insights may provide a promising therapeutic or maybe preventive approach of the pathogenic mtDNA removal in homoplasmic or heteroplasmic cells. Additional caveat is that this strategy may also use not only for cancer but also many other mitochondria related diseases, such as neurodegenerative, diabetic, renal, muscle and hearing loss diseases as well as aging. Citation Format: Hiroki Nagase. Cancer therapeutic and prevention strategy targeting mutated mitochondria DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5980.

Anti-replicative recombinant 5S rRNA molecules can modulate the mtDNA heteroplasmy in a glucose-dependent manner

Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion.

87 Overexpression of mitochondrial Leucyl-tRNA synthetase restore the mitochondrial dysfunctions caused by the MELAS-associated tRNALeu(UUR) A3243G mutation

STEM CELLS ® EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Induced Pluripotent Stem Cells with a Pathological Mitochondrial DNA Deletion

Multilevel Functional and Structural Defects Induced by Two Pathogenic Mitochondrial Trna Mutations

Lysosomal uptake of mtDNA mitigates heteroplasmy

Mutations in MTO2 Related to Trna Modification Impair Mitochondrial Gene Expression and Protein Synthesis in the Presence of a Paromomycin Resistance Mutation in Mitochondrial 15 S Rrna

Abstract P23: Mitochondrial Delivery of Functional Nucleic Acids for Targeting of Mitochondrial Dysfunction

Engineering mtDNA Deletions by Reconstituting End-Joining in Human Mitochondria

Targeted deletions in human mitochondrial DNA engineered by Type V CRISPR-Cas12a system

Capture of Somatic mtDNA Point Mutations with Severe Effects on Oxidative Phosphorylation in Synaptosome Cybrid Clones from Human Brain

Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations

Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy

Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing

Metabolic Rescue in Pluripotent Cells from Patients with Mtdna Disease

Molecular Basis of the Pathogenic Mechanism Induced by the m.9191T>C Mutation in Mitochondrial ATP6 Gene

Single-cell analysis reveals context-dependent, cell-level selection of mtDNA

Deregulating Mitochondrial Metabolite and Ion Transport Has Beneficial Effects in Yeast and Human Cellular Models for NARP Syndrome

Direct Evidence of CRISPR-Cas9-mediated Mitochondrial Genome Editing

Significant decrease of maternal mitochondria carryover using optimized spindle-chromosomal complex transfer

Abstract 5980: Cancer therapeutic and prevention strategy targeting mutated mitochondria DNA